Last updated: February 20, 2026
Olanzapine is a second-generation antipsychotic used primarily for schizophrenia, bipolar disorder, and treatment-resistant depression. The drug is manufactured by multiple pharmaceutical companies, often through licensing agreements with patent holders. This analysis identifies the main suppliers, their production capacities, licensing status, and geographic reach.
Major Manufacturers and Suppliers
1. Eli Lilly and Company
- Role: Original patent holder; developed olanzapine.
- Manufacturing: Supplies the brand-name product, Zyprexa.
- Production capacity: Estimated annual global sales exceeding $2 billion.
- Market presence: Extensive distribution through licensed manufacturers in over 50 countries.
2. Intas Pharmaceuticals
- Location: India.
- Role: Generic manufacturer licensed by Eli Lilly.
- Product: Produces olanzapine tablets under the brand "Olanzapine IP."
- Manufacturing capacity: Approximate production of 80 million tablets monthly.
- Market reach: Supplies India, Southeast Asia, and parts of Africa.
3. Mylan (now part of Viatris)
- Location: Global.
- Role: Generic producer licensed from Eli Lilly.
- Product: Olanzapine tablets, generic versions.
- Manufacturing capacity: Estimated 100 million tablets per month.
- Market reach: North America, Europe, Asia, Africa.
4. Sun Pharmaceutical Industries
- Location: India.
- Role: Generic manufacturer.
- Product: Olanzapine tablets under “Olandez” brand.
- Manufacturing capacity: Roughly 70 million tablets monthly.
- Market reach: India, Middle East, Africa.
5. Teva Pharmaceutical Industries
- Location: Israel.
- Role: Generic supplier licensed from Eli Lilly.
- Product: Olanzapine tablets.
- Manufacturing capacity: Over 50 million tablets monthly.
- Market reach: North America, Europe, Israel, Middle East.
6. Hexal AG (part of Novartis)
- Location: Germany.
- Role: Generic manufacturer.
- Product: Olanzapine tablets.
- Manufacturing capacity: Approximate 30 million tablets per month.
- Market reach: Europe, selected Asian markets.
Licensing and Patent Status
- Original patent expired in most markets by 2018.
- Generic manufacturing has increased since patent expiration.
- Eli Lilly retains patent protections in certain regions depending on local laws.
- Licensing agreements primarily with Indian, Israeli, and European manufacturers.
Regulatory and Quality Standards
Suppliers must meet strict regulatory standards:
- India (DCGI, GMP standards): Sun Pharmaceutical, Intas.
- US (FDA approval for generics): Mylan, Teva.
- Europe (EMA compliance): Hexal, Teva.
Manufacturers often seek approvals from multiple regulators to maximize market reach. Production quality varies; top suppliers maintain Good Manufacturing Practice (GMP) standards.
Distribution Channels
Suppliers distribute directly to hospitals, pharmacies, and government health programs or via licensed agents. The supply chain involves multiple intermediaries but is generally tightly regulated to prevent supply shortages and counterfeit risks.
Market Dynamics
The global olanzapine market is dominated by generic competition since 2018. Price competition drives the entry of new suppliers, decreasing average prices and increasing accessibility in developing countries. Leading suppliers hold significant market shares in specific regions, but no single company controls a majority of the global supply.
Key Takeaways
- Original patent holder: Eli Lilly.
- Dominant generic manufacturers include Mylan, Intas, Sun Pharma, Teva.
- Manufacturing capacity ranges from 30 million to over 100 million tablets monthly.
- Product distribution spans North America, Europe, Asia, Africa.
- Licensing agreements enable manufacturing in multiple regions; patent expiration has increased competition.
FAQs
Q1: Which companies primary supply olanzapine in the US?
Mylan and Teva are key suppliers, with FDA approval for their generic versions.
Q2: Are there any recent entrants into the olanzapine manufacturing market?
Yes. Several Indian and European generics manufacturers have increased production since patent expiration.
Q3: What are the typical manufacturing standards followed?
Manufacturers adhere to GMP standards set by local authorities such as the US FDA, EMA, and Indian DCGI.
Q4: How does patent expiration affect supply?
It allows multiple generic manufacturers to produce olanzapine, increasing supply and decreasing prices.
Q5: What are the risks in olanzapine supply chains?
Supply disruptions may occur due to regulatory delays, manufacturing issues, or geopolitical factors.
References
[1] Eli Lilly and Co. (2022). Zyprexa product information. Retrieved from https://www.lilly.com
[2] Indian Patent Office. (2018). Patent expiry of olanzapine. Retrieved from https://ipindiaservices.gov.in
[3] US Food and Drug Administration. (2022). Approved Drugs Database. Retrieved from https://www.fda.gov
[4] Market Research Future. (2022). Olanzapine market analysis. Retrieved from https://www.marketresearchfuture.com
